Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of immunology-based therapies for patients with immune-mediated diseases. The company operates within the biotechnology and pharmaceutical industries, with a core emphasis on autoimmune and inflammatory disorders. Its business model centers on advancing differentiated biologic and small-molecule drug candidates through clinical development, with future revenue expected to be driven primarily by product commercialization and potential strategic partnerships.
The company’s primary focus is on developing targeted therapies designed to modulate immune system pathways implicated in chronic and severe diseases. Zenas BioPharma positions itself through a strategy of in-licensing or acquiring promising assets and advancing them efficiently through clinical trials. The company was founded in 2019 and has since evolved into a publicly traded entity, completing an initial public offering in 2023, which provided capital to advance its pipeline and expand operations.
Business Operations
Zenas BioPharma’s operations are organized around research and development activities rather than commercial sales, as the company does not yet have approved products generating material revenue. Its core business involves preclinical research, clinical trial execution, regulatory strategy, and intellectual property management related to its immunology-focused pipeline. The company conducts clinical trials through a combination of internal expertise and third-party contract research organizations, primarily in North America and select international markets.
The company’s asset portfolio includes multiple development-stage therapeutic candidates targeting immune system dysregulation. Zenas BioPharma relies on a network of academic collaborators, clinical investigators, and manufacturing partners to support drug development and clinical supply. As of the latest publicly available disclosures, the company operates as a single reporting segment and does not report material revenue from product sales.
Strategic Position & Investments
Zenas BioPharma’s strategic direction emphasizes advancing its lead clinical programs through key development milestones while selectively expanding its pipeline through acquisitions or licensing transactions. The company has invested heavily in clinical development infrastructure and regulatory capabilities to support late-stage trials and potential future commercialization. Growth initiatives are centered on demonstrating clinical efficacy and safety in targeted indications to increase asset value.
The company has pursued asset-focused investments rather than broad platform development, allowing it to concentrate capital on programs with defined clinical and regulatory pathways. Notable investments include the acquisition or licensing of proprietary drug candidates that form the foundation of its current pipeline. Data regarding additional portfolio companies or minority equity investments is inconclusive based on available public sources.
Geographic Footprint
Zenas BioPharma is headquartered in the United States, with its principal executive offices located in Waltham, Massachusetts. The company’s operational footprint is primarily concentrated in North America, where most of its research, development, and corporate functions are based.
Internationally, Zenas BioPharma maintains a limited but growing presence through clinical trial activities conducted in select regions outside the United States, including parts of Europe. These international activities are primarily related to patient enrollment and regulatory engagement rather than permanent operational facilities.
Leadership & Governance
Zenas BioPharma is led by an executive team with experience in biotechnology, pharmaceutical development, and capital markets. The leadership’s strategic vision centers on disciplined clinical execution, value-driven asset selection, and long-term value creation through innovation in immunology.
Key executives include:
- Lonnie Moulder – Chief Executive Officer
- Jerel Davis – President
- Robert Li – Chief Financial Officer
- Paul Delost – Chief Operating Officer
- Daniel Faga – Chief Medical Officer
The company is governed by a board of directors composed of industry executives and investors with experience in drug development, corporate governance, and life sciences investing.